Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 417,841
  • Shares Outstanding, K 266,141
  • Annual Sales, $ 10,120 K
  • Annual Income, $ -220,660 K
  • EBIT $ -263 M
  • EBITDA $ -255 M
  • 60-Month Beta 2.01
  • Price/Sales 38.92
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 353.68% (-53.09%)
  • Historical Volatility 88.58%
  • IV Percentile 78%
  • IV Rank 45.02%
  • IV High 697.19% on 11/10/25
  • IV Low 72.43% on 05/20/25
  • Expected Move (DTE 14) 0.2380 (15.35%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 113
  • Volume Avg (30-Day) 450
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 20,918
  • Open Int (30-Day) 18,923
  • Expected Range 1.3120 to 1.7880

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.32
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -177.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +29.17%
on 11/21/25
1.6100 -3.73%
on 12/04/25
+0.1700 (+12.32%)
since 11/05/25
3-Month
1.2000 +29.17%
on 11/21/25
1.8000 -13.89%
on 10/09/25
+0.0900 (+6.16%)
since 09/05/25
52-Week
1.1050 +40.27%
on 04/11/25
3.0800 -49.68%
on 12/09/24
-1.3700 (-46.92%)
since 12/05/24

Most Recent Stories

More News
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Company reports Q3 2025 AUCATZYL ® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase...

AUTL : 1.5500 (-1.27%)
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.5500 (-1.27%)
AVAI : 0.2875 (-2.58%)
DNLI : 19.96 (-0.75%)
EDIT : 2.42 (-0.41%)
XNCR : 17.30 (-4.63%)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.5500 (-1.27%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.6567
2nd Resistance Point 1.6233
1st Resistance Point 1.5867
Last Price 1.5500
1st Support Level 1.5167
2nd Support Level 1.4833
3rd Support Level 1.4467

See More

52-Week High 3.0800
Fibonacci 61.8% 2.3255
Fibonacci 50% 2.0925
Fibonacci 38.2% 1.8594
Last Price 1.5500
52-Week Low 1.1050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar